NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
1.195
-0.015 (-1.23%)
Nov 21, 2024, 12:08 PM EST - Market open
NRx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 1.65 | 4.6 | 20.05 | 27.61 | 1.86 | 0.88 |
Cash & Short-Term Investments | 1.65 | 4.6 | 20.05 | 27.61 | 1.86 | 0.88 |
Cash Growth | -81.51% | -77.09% | -27.35% | 1384.94% | 111.87% | - |
Other Receivables | - | 0.01 | 0.01 | - | 0.83 | - |
Receivables | - | 0.01 | 0.01 | - | 0.83 | - |
Prepaid Expenses | 2.46 | 1.41 | 3.77 | 4.6 | 0.21 | 0.1 |
Other Current Assets | - | 0.87 | 1.97 | 0.51 | 0.03 | - |
Total Current Assets | 4.11 | 6.88 | 25.8 | 32.71 | 2.93 | 0.98 |
Other Long-Term Assets | 0.36 | 0.43 | 0.02 | 0.02 | 0.01 | 0.01 |
Total Assets | 4.46 | 7.32 | 25.82 | 32.73 | 2.94 | 0.99 |
Accounts Payable | 4.87 | 4.63 | 2.08 | 3.69 | 3.15 | 2.07 |
Accrued Expenses | 10.48 | 5.24 | 5.77 | 2.84 | 3.28 | 0.01 |
Short-Term Debt | 3.05 | - | - | - | - | 0.15 |
Current Portion of Long-Term Debt | - | 9.16 | 7.7 | 0.52 | 0.25 | 0.13 |
Other Current Liabilities | 1.9 | 0.02 | 0.04 | 4.87 | 39.49 | 0.01 |
Total Current Liabilities | 20.3 | 19.05 | 15.59 | 11.92 | 46.16 | 2.38 |
Long-Term Debt | 2.99 | - | 2.82 | - | 0.55 | 3.46 |
Total Liabilities | 23.28 | 19.05 | 18.41 | 11.92 | 46.71 | 5.84 |
Common Stock | 0.01 | 0.08 | 0.07 | 0.06 | 0.04 | 0.01 |
Additional Paid-In Capital | 250.36 | 241.33 | 230.34 | 203.99 | 46.37 | 33.54 |
Retained Earnings | -269.2 | -253.15 | -223 | -183.24 | -90.18 | -38.4 |
Comprehensive Income & Other | - | -0 | - | - | - | - |
Total Common Equity | -18.82 | -11.74 | 7.41 | 20.81 | -43.77 | -4.85 |
Shareholders' Equity | -18.82 | -11.73 | 7.41 | 20.81 | -43.77 | -4.85 |
Total Liabilities & Equity | 4.46 | 7.32 | 25.82 | 32.73 | 2.94 | 0.99 |
Total Debt | 6.04 | 9.16 | 10.53 | 0.52 | 0.8 | 3.75 |
Net Cash (Debt) | -4.39 | -4.57 | 9.53 | 27.09 | 1.06 | -2.87 |
Net Cash Growth | - | - | -64.82% | 2450.56% | - | - |
Net Cash Per Share | -0.46 | -0.60 | 1.45 | 5.77 | 0.31 | -2.68 |
Filing Date Shares Outstanding | 12.09 | 9.45 | 7.06 | 6.66 | 11.83 | 1.07 |
Total Common Shares Outstanding | 11.37 | 8.27 | 6.54 | 5.88 | 11.23 | 1.07 |
Working Capital | -16.19 | -12.16 | 10.21 | 20.79 | -43.23 | -1.4 |
Book Value Per Share | -1.65 | -1.42 | 1.13 | 3.54 | -3.90 | -4.54 |
Tangible Book Value | -18.82 | -11.74 | 7.41 | 20.81 | -43.77 | -4.85 |
Tangible Book Value Per Share | -1.65 | -1.42 | 1.13 | 3.54 | -3.90 | -4.54 |
Source: S&P Capital IQ. Standard template. Financial Sources.